Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 7,763,720, with claims related to DNAs encoding the novel molecular aspects of the Company's NPC-1 antibody.
“This additional patent further enhances the Company's growing library of varied patents of different aspects of several antibody lines. The Company believes that the strength and diversity of its Patent Library is an important part of what separates it from other emerging companies working in similar areas of research”
"This additional patent further enhances the Company's growing library of varied patents of different aspects of several antibody lines. The Company believes that the strength and diversity of its Patent Library is an important part of what separates it from other emerging companies working in similar areas of research," said Neogenix President and Chief Executive Officer, Philip M. Arlen, MD.
The USPTO has previously granted a patent for the NPC-1C monoclonal antibody (ensituximab) as well as a patent related to the 31.1 monoclonal antibody.
A Phase I therapeutic trial is being conducted to evaluate the clinical safety of the NPC-1C antibody in patients with metastatic pancreatic and colorectal cancer In addition, a clinical study to establish NPC-1C and certain other proprietary antibodies as serum diagnostics for pancreatic and colorectal cancers is currently underway.
Study reveals why COVID-19 antibodies fade quickly